Methylation & Proteomics-Based Detection of Bladder Cancer
226
- Cairns, Paul — Fox Chase Cancer Center
- Bochner, Bernard — Memorial Sloan-Kettering Cancer Center
- Feng, Ziding — Fred Hutchinson Cancer Research Center
- Helber, Sarah — AIBioTech
- Steinberg, Gary D. — University of Chicago Urology Center
- Wei, John — University of Michigan
- Wagner, Andrew — Beth Israel Deaconess Medical Center
- Schoenberg, Mark P. — Johns Hopkins University
- Kibel, Adam — Brigham and Women's Hospital
- Sidransky, David — Johns Hopkins University School of Medicine
- Srivastava, Sudhir — National Cancer Institute
- Shore, Neal — CURC/Carolina Urologic Research Center
- Thompson, Ian M. — University of Texas Health Science Center at San Antonio
- Czerniak, Bogdan — The University of Texas MD Anderson Cancer Center
Case/control
Hypermethylation
Prostate and Urologic Cancers Research Group
1
To determine sensitivity and specificity of quantitative real-time methylation specific PCR (qMSP) of urine sediment DNA, using a panel of several methylated gene markers, in detecting bladder cancer in participants pathologically confirmed to have this disease. Secondary objective: to test the sensitivity and specificity of an Aurora A FISH probe for the detection of clinically evident bladder cancer.
This study will test the sensitivity of gene methylation in the presence of clinically evident, pathologically confirmed bladder cancer.
This study will test the specificity of gene methylation in two groups of participants without bladder cancer - requiring cystoscopy for hematuria and for foreign body (urinary stones, stents, and catheters) or infection.
Quantitative real time methylation specific PCR (qMSP) of urine sediment DNA using a panel of several methylated gene markers.
There are currently no biomarkers annotated for this protocol.
No datasets are currently associated with this protocol.
